BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36682147)

  • 21. A novel small-molecule PI3K/Akt signaling inhibitor, W934, exhibits potent antitumor efficacy in A549 non-small-cell lung cancer.
    Wang J; Wang HY; Shen Y; Liang D; Wang HY; Zhang SQ; Cao YX; Cao L
    Anticancer Drugs; 2019 Oct; 30(9):900-908. PubMed ID: 30913062
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and Anti-Proliferative Evaluations of New Heterocyclic Derivatives Using 5,6,8,9-Tetrahydropyrazolo[5,1-b]quinazolin-7(3H)-one Derivatives Derived from Cyclohexa-1,4-dione.
    Mahmoud MAA; Alsharif MA; Mohareb RM
    Anticancer Agents Med Chem; 2021; 21(4):468-486. PubMed ID: 32445457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting BET proteins inhibited the growth of non-small cell lung carcinoma through downregulation of Met expression.
    Yuan T; Ni P; Zhang Z; Wu D; Sun G; Zhang H; Chen B; Wang X; Cheng Z
    Cell Biol Int; 2023 Mar; 47(3):622-633. PubMed ID: 36448366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis and biological evaluation of novel series of 2H-benzo[b][1,4]oxazin-3(4H)-one and 2H-benzo[b][1,4]oxazine scaffold derivatives as PI3Kα inhibitors.
    Dong FD; Liu DD; Deng CL; Qin XC; Chen K; Wang J; Song HR; Ding HW
    Bioorg Med Chem; 2018 Aug; 26(14):3982-3991. PubMed ID: 29937355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel class of pyrazole analogues as aurora kinase A inhibitor: design, synthesis, and anticancer evaluation.
    Yevale DB; Teraiya N; Lalwani TD; Ameta RK; Sangani CB
    Bioorg Chem; 2023 Dec; 141():106901. PubMed ID: 37797455
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis and evaluation of some 1,6-disubstituted-1H-benzo[d]imidazoles derivatives targeted PI3K as anticancer agents.
    Ding HW; Yu L; Bai MX; Qin XC; Song MT; Zhao QC
    Bioorg Chem; 2019 Dec; 93():103283. PubMed ID: 31585260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and antitumor activity evaluation of PI3K inhibitors containing 3-substituted quinazolin-4(3H)-one moiety.
    Zhang H; Xin MH; Xie XX; Mao S; Zuo SJ; Lu SM; Zhang SQ
    Bioorg Med Chem; 2015 Dec; 23(24):7765-76. PubMed ID: 26652969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sulfonamide-based 4-anilinoquinoline derivatives as novel dual Aurora kinase (AURKA/B) inhibitors: Synthesis, biological evaluation and in silico insights.
    Al-Sanea MM; Elkamhawy A; Paik S; Lee K; El Kerdawy AM; Syed Nasir Abbas B; Joo Roh E; Eldehna WM; Elshemy HAH; Bakr RB; Ali Farahat I; Alzarea AI; Alzarea SI; Alharbi KS; Abdelgawad MA
    Bioorg Med Chem; 2020 Jul; 28(13):115525. PubMed ID: 32371117
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Thongsom S; Racha S; Ei ZZ; Petsri K; Aksorn N; Chamni S; Panpuang V; Zou H; Chanvorachote P
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino-N-(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents.
    Peng W; Tu ZC; Long ZJ; Liu Q; Lu G
    Eur J Med Chem; 2016 Jan; 108():644-654. PubMed ID: 26731167
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A New Series of Triazolothiadiazines as Potential Anticancer Agents for Targeted Therapy of Non-Small Cell Lung and Colorectal Cancers: Design, Synthesis, In silico and In vitro Studies Providing Mechanistic Insight into Their Anticancer Potencies.
    Sever B; Altıntop MD; Çiftçi GA; Özdemir A
    Med Chem; 2021; 17(10):1104-1128. PubMed ID: 33087032
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.
    Wang NY; Xu Y; Xiao KJ; Zuo WQ; Zhu YX; Hu R; Wang WL; Shi YJ; Yu LT; Liu ZH
    Eur J Med Chem; 2020 Apr; 191():112152. PubMed ID: 32088495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis and in silico insights of new 7,8-disubstituted-1,3-dimethyl-1H-purine-2,6(3H,7H)-dione derivatives with potent anticancer and multi-kinase inhibitory activities.
    Mohamed AR; El Kerdawy AM; George RF; Georgey HH; Abdel Gawad NM
    Bioorg Chem; 2021 Feb; 107():104569. PubMed ID: 33387732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis and biological evaluation of imidazolopyridone derivatives as novel BRD4 inhibitors.
    Yang Y; Chen P; Zhao L; Zhang B; Xu C; Zhang H; Zhou J
    Bioorg Med Chem; 2021 Jan; 29():115857. PubMed ID: 33191086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-based drug design: Synthesis and biological evaluation of quinazolin-4-amine derivatives as selective Aurora A kinase inhibitors.
    Long L; Wang YH; Zhuo JX; Tu ZC; Wu R; Yan M; Liu Q; Lu G
    Eur J Med Chem; 2018 Sep; 157():1361-1375. PubMed ID: 30196060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis, biological evaluation and structure-activity relationship of a novel class of PI3Kα H1047R mutant inhibitors.
    Zhang N; Yu Z; Yang X; Zhou Y; Wang J; Zhang SL; Wang MW; He Y
    Eur J Med Chem; 2018 Oct; 158():707-719. PubMed ID: 30245395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-Based Design: Synthesis, X-ray Crystallography, and Biological Evaluation of N-Substituted-4-Hydroxy-2-Quinolone-3-Carboxamides as Potential Cytotoxic Agents.
    Sabbah DA; Hishmah B; Sweidan K; Bardaweel S; AlDamen M; Zhong HA; Abu Khalaf R; Hasan Ibrahim A; Al-Qirim T; Abu Sheikha G; Mubarak MS
    Anticancer Agents Med Chem; 2018; 18(2):263-276. PubMed ID: 28901259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases.
    Sahni JM; Gayle SS; Bonk KL; Vite LC; Yori JL; Webb B; Ramos EK; Seachrist DD; Landis MD; Chang JC; Bradner JE; Keri RA
    J Biol Chem; 2016 Nov; 291(45):23756-23768. PubMed ID: 27650498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
    Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, Synthesis and Bioevaluation of Two Series of 3-[(1-Benzyl-1H-1,2,3-triazol-4-yl)methyl]quinazolin-4(3H)-ones and N-(1-Benzylpiperidin-4-yl)quinazolin-4-amines.
    Lan TT; Anh DT; Pham-The H; Dung DTM; Park EJ; Jang SD; Kwon JH; Kang JS; Thuan NT; Han SB; Nam NH
    Chem Biodivers; 2020 Jul; 17(7):e2000290. PubMed ID: 32356584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.